Ausgabe 2/2019
Inhalt (26 Artikel)
Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases
Zhe-Bin Liu, Nader E. Ezzedine, Agda K. Eterovic, Joe E. Ensor, Helen J. Huang, Joan Albanell, Dong S. Choi, Ana Lluch, Yi Liu, Federico Rojo, Helen Wong, Eduardo Martínez-Dueñas, Ángel Guerrero-Zotano, Zhi-Min Shao, Jorge G. Darcourt, Gordon B. Mills, Bhuvanesh Dave, Jenny C. Chang
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
Jichao He, Ronan P. McLaughlin, Vera van der Noord, John A. Foekens, John W. M. Martens, Gerard van Westen, Yinghui Zhang, Bob van de Water
HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
Yuanyuan Liu, Shafei Wu, Xiaohua Shi, Yufeng Luo, Junyi Pang, Changjun Wang, Feng Mao, Zhiyong Liang, Xuan Zeng
Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer
Akira I. Hida, Takahiro Watanabe, Yasuaki Sagara, Masahiro Kashiwaba, Yoshiaki Sagara, Kenjiro Aogi, Yasuyo Ohi, Akihide Tanimoto
Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence
Chi Peng Timothy Lai, Joe Poh Sheng Yeong, An Sen Tan, Chong Hui Clara Ong, Bernett Lee, Jeffrey Chun Tatt Lim, Aye Aye Thike, Jabed Iqbal, Rebecca Alexandra Dent, Elaine Hsuen Lim, Puay Hoon Tan
Genomic landscape of ductal carcinoma in situ and association with progression
Chieh-Yu Lin, Sujay Vennam, Natasha Purington, Eric Lin, Sushama Varma, Summer Han, Manisha Desa, Tina Seto, Nicholas J. Wang, Henning Stehr, Megan L. Troxell, Allison W. Kurian, Robert B. West
Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse
Chidananda M. Siddappa, Sreeraj G. Pillai, Jackie Snider, Patsy Alldredge, Kathyrn Trinkaus, Mark A. Watson, Rebecca Aft
A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients
Angel Arnaout, Susan J. Robertson, Gregory R. Pond, Hoyun Lee, Ahwon Jeong, Luisa Ianni, Lynne Kroeger, John Hilton, Stuart Coupland, Chloe Gottlieb, Bernard Hurley, Anne McCarthy, Mark Clemons
A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy
Andrew Robinson, Carol Stober, Dean Fergusson, Anne Kehoe, Debbie Bedard, Fiona MacDonald, Marie-Claude Brunet, Deanna Saunders, Sasha Mazzarello, Lisa Vandermeer, Anil A. Joy, Arif Awan, Bassam Basulaiman, Ranjeeta Mallick, Brian Hutton, Mark Clemons
Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients
Angel Arnaout, Susan Robertson, Gregory R. Pond, Reinhold Vieth, Ahwon Jeong, John Hilton, Timothy Ramsey, Mark Clemons
Phase II randomized controlled trial of hypnosis versus progressive muscle relaxation for body image after breast or gynecologic cancer
Debra L. Barton, Trevor M. Brooks, Alison Cieslak, Gary R. Elkins, Patricia M. Clark, Mohamad Baydoun, Asa B. Smith, Catherine H. Van Poznak
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
Ji-Yeon Kim, Eunjin Lee, Kyunghee Park, Seock-Ah Im, Joohyuk Sohn, Keun Seok Lee, Yee Soo Chae, Jee Hyun Kim, Tae-Yong Kim, Kyung Hae Jung, Yeon Hee Park
Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database
Yan-ling Liu, Dun-wei Wang, Zhu-chun Yang, Rui Ma, Zhong Li, Wei Suo, Zhuang Zhao, Zhi-wen Li
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
Sandra M. Swain, Gong Tang, Peter C. Lucas, André Robidoux, David Goerlitz, Brent T. Harris, Hanna Bandos, Charles E. Geyer Jr., Priya Rastogi, Eleftherios P. Mamounas, Norman Wolmark
Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience
Nicolò Matteo Luca Battisti, Daniel Tong, Alistair Ring, Ian Smith
Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study
Gurdeep S. Mannu, Emma J. Groen, Zhe Wang, Michael Schaapveld, Esther H. Lips, Monica Chung, Ires Joore, Flora E. van Leeuwen, Hendrik J. Teertstra, Gonneke A. O. Winter-Warnars, Sarah C. Darby, Jelle Wesseling
Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States
Ashley C. Pariser, Tannaz Sedghi, Pamela R. Soulos, Brigid Killelea, Cary P. Gross, Sarah S. Mougalian
Allelic modification of breast cancer risk in women with an NBN mutation
Bogna Rusak, Wojciech Kluźniak, Dominika Wokołorczyk, Klaudia Stempa, Aniruddh Kashyap, Helena Rudnicka, Jacek Gronwald, Tomasz Huzarski, Tadeusz Dębniak, Anna Jakubowska, Marek Szwiec, Mohammad R. Akbari, Steven A. Narod, Jan Lubiński, Cezary Cybulski, J. Mituś, Z. Morawiec, S. Niepsuj, R. Sibilski, M. Siołek, J. Sir, D. Surdyka, A. Synowiec, C. Szczylik, R. Uciński, B. Waśko, R. Wiśniowski, T. Byrski, B. Górski, M. Lener, J. Tomiczek-Szwiec, J. Jarkiewicz-Tretyn, M. Cechowska, P. Domagała
Differences in breast cancer outcomes amongst Black US-born and Caribbean-born immigrants
Priscila Barreto-Coelho, Danielle Cerbon, Matthew Schlumbrecht, Carlos M. Parra, Judith Hurley, Sophia H. L. George
Time-to-surgery and overall survival after breast cancer diagnosis in a universal health system
Yvonne L. Eaglehouse, Matthew W. Georg, Craig D. Shriver, Kangmin Zhu
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes
Giuseppe Viale, Amy E. Hanlon Newell, Espen Walker, Greg Harlow, Isaac Bai, Leila Russo, Patrizia Dell’Orto, Patrick Maisonneuve
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
Christine Lundgren, Pär-Ola Bendahl, Åke Borg, Anna Ehinger, Cecilia Hegardt, Christer Larsson, Niklas Loman, Martin Malmberg, Helena Olofsson, Lao H. Saal, Tobias Sjöblom, Henrik Lindman, Marie Klintman, Jari Häkkinen, Johan Vallon-Christersson, Mårten Fernö, Lisa Rydén, Maria Ekholm
Rationale for evaluating breast cancers of Lynch syndrome patients for mismatch repair gene expression
Steven Sorscher
Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients
Ethan Tang, Andrew Rowland, Ross A. McKinnon, Michael J. Sorich, Ashley M. Hopkins
Precision medicine: PI3K targeting in advanced breast cancer
Andrea Rocca, Elisabetta Melegari, Michela Palleschi
Letter regarding Sopik V et al. entitled “Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ”
Xiangyu Wang, Xiangyi Kong, Yi Fang, Jing Wang